Overview
C. difficile Infection and Recurrence: Targeting the Drivers of Pathogenesis
Insights & Updates in the Treatment and Prevention of Recurrent CDI
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Clostridium difficile infection (CDI) is associated with significant morbidity and mortality. Recurrence is common after an initial episode. Although a number of therapies with varying mechanisms of action, are available to treat CDI and prevent recurrence, the management of CDI is complex and challenging. To address these challenges, IDSA/SHEA recently updated their guidelines to include new data and more aggressive approaches to treatment. Clinicians require up-to-date knowledge of evidence-based treatment of initial and recurrent CDI to improve clinical outcomes. In this CME eNewsletter, Dr. Paul Feuerstadt will discuss the body’s defenses against C. difficile infection, including the immune response and changes in the gut microbiome. This is the final activity in a series of three educational activities on CDI released in 2018.
This activity is intended for gastroenterologists, infectious disease specialists and other healthcare professionals that treat clostridium difficile infections.
The purpose of this activity is to update physicians on the body’s defenses against C. difficile infection, including the immune response and changes in the gut microbiome, as well as the effect of available therapies on these processes during the treatment of initial and recurrent episodes of C. difficile
Upon completion of this activity, participants will be able to:
• Discuss changes in the gut microbiome during C. difficile infection and treatment
• Describe the role of antimicrobials and antitoxins in the prevention of recurrent C. difficile infection
• Outline approaches that have been investigated to restore the gut microbiome for the treatment of C. difficile
• Discuss changes in the gut microbiome during C. difficile infection and treatment
• Describe the role of antimicrobials and antitoxins in the prevention of recurrent C. difficile infection
• Outline approaches that have been investigated to restore the gut microbiome for the treatment of C. difficile
Supported by an educational grant from Merck & Co., Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Download Adobe Flash Player.
5. Adobe Reader to print certificate. Download Adobe Reader.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Download Adobe Flash Player.
5. Adobe Reader to print certificate. Download Adobe Reader.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Paul Feuerstadt, MD
Attending Physician
Gastroenterology Center of Connecticut
Hamden, CT
Assistant Clinical Professor of Medicine
Gastroenterology, Yale University School of Medicine
New Haven, CT
Attending Physician
Gastroenterology Center of Connecticut
Hamden, CT
Assistant Clinical Professor of Medicine
Gastroenterology, Yale University School of Medicine
New Haven, CT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational agents for the treatment of C. difficile.
The following financial relationships have been provided:
Paul Feuerstadt, MD (Faculty)
Speakers Bureau: Merck & Company
Consulting: Merck & Company, Seres Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational agents for the treatment of C. difficile.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
